Last reviewed · How we verify
MK-2828
At a glance
| Generic name | MK-2828 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) (PHASE1)
- A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) (PHASE1)
- A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) (PHASE1)
- Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-2828 CI brief — competitive landscape report
- MK-2828 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI